tailieunhanh - báo cáo hóa học:" Pain in castration-resistant prostate cancer with bone metastases: a qualitative study"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí hóa học đề tài : Pain in castration-resistant prostate cancer with bone metastases: a qualitative study | Gater et al. Health and Quality of Life Outcomes 2011 9 88 http content 9 1 88 HEALTH AND QUALITY OF LIFE OUTCOMES RESEARCH Open Access Pain in castration-resistant prostate cancer with bone metastases a qualitative study 1 1 2 3 2 2 Adam Gater Linda Abetz-Webb Clare Battersby Bhash Parasuraman Stuart McIntosh Faith Nathan and Elisabeth C Piault4 Abstract Background Bone metastases are a common painful and debilitating consequence of castration-resistant prostate cancer CPRC . Bone pain may predict patients prognosis and there is a need to further explore CRPC patients experiences of bone pain in the overall context of disease pathology. Due to the subjective nature of pain assessments of pain severity onset and progression are reliant on patient assessment. Patient reported outcome PRO measures therefore are commonly used as key endpoints for evaluating the efficacy of CRPC treatments. Evidence of the content validity of leading PRO measures of pain severity used in CRPC clinical trials is however limited. Methods To document patients experience of CRPC symptoms including pain and their impact on health-related quality of life HRQL semi-structured in-depth qualitative interviews were conducted with 17 patients with CRPC and bone metastases. The content validity of the Present Pain Intensity PPI scale from the McGill Pain Questionnaire MPQ and the Average Pain and Worst Pain items of the Brief Pain Inventory Short-Form BPI-SF was also assessed. Results Patients with CRPC and bone metastases present with a constellation of symptoms that can have a profound effect on HRQL. For patients in this study bone pain was the most prominent and debilitating symptom associated with their condition. Bone pain was chronic and despite being generally well-managed by analgesic medication instances of breakthrough cancer pain BTcP were common. Cognitive debriefing of the selected PRO measures of pain severity highlighted difficulties among patients in understanding the